aTyr Pharma, Inc.
LIFE$352M
Small CapNASDAQInsurance Agents, Brokers & Service🇺🇸North AmericaAUSTIN548 employees
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
LIFE News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Efzofitimod 3 mg/kg
Pulmonary Sarcoidosis
ATYR1940
Limb-Girdle Muscular Dystrophies
efzofitimod 450 mg
Interstitial Lung Disease
Efzofitimod 1 mg/kg
SARS-CoV-2 (COVID-19) Severe Pneumonia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efzofitimod 3 mg/kg | Phase 3 | Pulmonary Sarcoidosis | - | - |
ATYR1940 | Phase 2 | Limb-Girdle Muscular Dystrophies | - | - |
efzofitimod 450 mg | Phase 2 | Interstitial Lung Disease | - | - |
Efzofitimod 1 mg/kg | Phase 2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply